César Cabezas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
César Cabezas has a total of 483 co-authors. Here are the top co-authors by number of shared publications:
- Nancy Arróspide
Instituto Nacional de Salud, Lima, Peru
9 shared publications - Salomón Durand
Área de Epidemiología, Dirección Regional de Salud Loreto , Iquitos
9 shared publications - Fernando Donaires
Centro Nacional de Salud Pública, Instituto Nacional de Salud. Lima, Perú
7 shared publications - Ronnie Gustavo Gavilan
Instituto Nacional de Salud
7 shared publications - Johanna Balbuena-Torres
National Reference Laboratory of Immunopreventable Viruses, Instituto Nacional de Salud, Lima 15066, Peru
6 shared publications - María Paquita García
National Reference Laboratory for Vector-borne and Viral Zoonotic Diseases, National Institute of Health, Lima, Peru
6 shared publications
Latest Publications
- Open Access
- 10 March 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (2)
Nucleic acid tests for scalable testing of blood donations for Oropouche virus in affluent and resource-limited settings
- 10 March 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (2)
Open AccessNucleic acid tests for scalable testing of blood donations for Oropouche virus in affluent and resource-limited settings
- Open Access
- 26 February 2026
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 43 (1) , 4-5
Excelencia editorial e impacto en salud pública: una mirada estratégica desde las revistas científicas del sur global
- 26 February 2026
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 43 (1) , 4-5
Open AccessExcelencia editorial e impacto en salud pública: una mirada estratégica desde las revistas científicas del sur global
- Open Access
- 17 November 2025
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 42 (4) , 347-8
Curiosidad enraizada en el territorio y servicio público: el legado del Dr. Paul Pachas
- 17 November 2025
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 42 (4) , 347-8
Open AccessCuriosidad enraizada en el territorio y servicio público: el legado del Dr. Paul Pachas
- Open Access
Genotypic Diversity of Hepatitis B and Delta Viruses in Peru: A Phylogenetic Study Using Next-Generation Sequencing
Objective: To characterize the molecular epidemiology and genomic diversity of hepatitis B virus (HBV) and hepatitis delta virus (HDV) in Peru using next-generation sequencing (NGS). Materials and Methods: A cross-sectional observational study was conducted using 209 serum/plasma samples from various regions of Peru, stored at the National Institute of Health. Detection of HBV and HDV was performed by PCR and RT-PCR, respectively. Nucleic acids were purified and quantified for library preparation and sequencing using the Illumina platform. Sequencing reads were aligned to reference genomes to determine genotypes, subgenotypes, and clinically relevant mutations. Geneious Prime was used for assembly and phylogenetic analysis, and STATA v.14.0 for statistical analysis. Results: HBV genotype F was the most prevalent (96.1%), with subgenotype F1b being predominant, followed by genotypes H, G, and C. Mutations associated with virulence and immune escape were identified, particularly A1762T/G1764A (66.7%) and A1762T/G1764A + G1896A (45.7%). All HDV sequences corresponded to genotype 3 (HDV-3), which was detected in six regions of the country. Conclusions: The findings confirm the predominant circulation of HBV genotype F and HDV genotype 3 in Peru, with genotypic diversity that may influence clinical outcomes, viral load, and response to treatment. Sustained molecular surveillance programs are recommended in endemic areas to guide control, treatment, and prevention strategies.
Open AccessGenotypic Diversity of Hepatitis B and Delta Viruses in Peru: A Phylogenetic Study Using Next-Generation Sequencing
Objective: To characterize the molecular epidemiology and genomic diversity of hepatitis B virus (HBV) and hepatitis delta virus (HDV) in Peru using next-generation sequencing (NGS). Materials and Methods: A cross-sectional observational study was conducted using 209 serum/plasma samples from various regions of Peru, stored at the National Institute of Health. Detection of HBV and HDV was performed by PCR and RT-PCR, respectively. Nucleic acids were purified and quantified for library preparation and sequencing using the Illumina platform. Sequencing reads were aligned to reference genomes to determine genotypes, subgenotypes, and clinically relevant mutations. Geneious Prime was used for assembly and phylogenetic analysis, and STATA v.14.0 for statistical analysis. Results: HBV genotype F was the most prevalent (96.1%), with subgenotype F1b being predominant, followed by genotypes H, G, and C. Mutations associated with virulence and immune escape were identified, particularly A1762T/G1764A (66.7%) and A1762T/G1764A + G1896A (45.7%). All HDV sequences corresponded to genotype 3 (HDV-3), which was detected in six regions of the country. Conclusions: The findings confirm the predominant circulation of HBV genotype F and HDV genotype 3 in Peru, with genotypic diversity that may influence clinical outcomes, viral load, and response to treatment. Sustained molecular surveillance programs are recommended in endemic areas to guide control, treatment, and prevention strategies.
- Open Access
- 20 June 2025
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 42 (2) , 113-4
Fiebre amarilla en el Perú y las américas, y el riesgo latente de su reurbanización: una amenaza evitable
- 20 June 2025
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 42 (2) , 113-4
Open AccessFiebre amarilla en el Perú y las américas, y el riesgo latente de su reurbanización: una amenaza evitable
- Open Access
- 18 June 2025
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 42 (2) , 223-4
Hepatitis C reinfection in patients with sustained virologic response at a national hospital in Peru, 2024
- 18 June 2025
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 42 (2) , 223-4
Open AccessHepatitis C reinfection in patients with sustained virologic response at a national hospital in Peru, 2024
- Open Access
First Detection of Oropouche Virus in Culicoides insignis in the Ucayali Region, Peru: Evidence of a Possible New Vector
This report details the first detection of the Oropouche virus (OROV) in Culicoides insignis in the Ucayali region (Peruvian Amazon) during an outbreak study in 2024. Captures conducted in peri-urban and rural areas showed that C. insignis accounted for 96.7% of the collected Culicoides specimens. RT-qPCR testing confirmed the presence of the virus in two C. insignis pools, establishing this species as a potential OROV vector in the study area, thereby contributing to the understanding of the virus’s epidemiology in the Amazon region.
Open AccessFirst Detection of Oropouche Virus in Culicoides insignis in the Ucayali Region, Peru: Evidence of a Possible New Vector
This report details the first detection of the Oropouche virus (OROV) in Culicoides insignis in the Ucayali region (Peruvian Amazon) during an outbreak study in 2024. Captures conducted in peri-urban and rural areas showed that C. insignis accounted for 96.7% of the collected Culicoides specimens. RT-qPCR testing confirmed the presence of the virus in two C. insignis pools, establishing this species as a potential OROV vector in the study area, thereby contributing to the understanding of the virus’s epidemiology in the Amazon region.
- Open Access
- 6 December 2024
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 41 (4) , 340-2
Prioridades nacionales de investigación en salud 2024-2030: una visión estratégica para el bienestar integral
- 6 December 2024
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 41 (4) , 340-2
Open AccessPrioridades nacionales de investigación en salud 2024-2030: una visión estratégica para el bienestar integral
- Open Access
- 4 December 2024
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 41 (4) , 375-84
Rapid spread of the emerging cosmopolitan genotype of dengue virus serotype 2, and expansion of dengue virus serotype 1 genotype V in Peru
Objectives. This study aimed to evaluate the prevalence and distribution of dengue virus genotype V serotype 1 (DENV-1) and cosmopolitan genotype serotype 2 (DENV-2) in Peru between 2019 and 2022. Materials and methods. The envelope (E) gene region was amplified from 79 serum samples by polymerase chain reaction (PCR) and sequenced by next-generation sequencing (NGS) technology. The obtained sequences were subsequently analyzed with bioinformatics tools. Results. The study generated envelope gene sequences of DENV-1 and DENV-2 serotypes. Our study revealed a rapid dispersal and wide distribution of the cosmopolitan DENV-2 genotype in several regions of Peru in 2022, as well as the spread of DENV-1 genotype V to new Peruvian regions, along with the cosmopolitan DENV-2 genotype. Conclusions. Our findings suggest the urgent need to strengthen epidemiological and genomic surveillance systems to understand and control the spread of circulating DENV genotypes in Peru. This will allow a more rapid response, as well as the monitoring of its potential dissemination to other countries in the Americas.
- 4 December 2024
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 41 (4) , 375-84
Open AccessRapid spread of the emerging cosmopolitan genotype of dengue virus serotype 2, and expansion of dengue virus serotype 1 genotype V in Peru
Objectives. This study aimed to evaluate the prevalence and distribution of dengue virus genotype V serotype 1 (DENV-1) and cosmopolitan genotype serotype 2 (DENV-2) in Peru between 2019 and 2022. Materials and methods. The envelope (E) gene region was amplified from 79 serum samples by polymerase chain reaction (PCR) and sequenced by next-generation sequencing (NGS) technology. The obtained sequences were subsequently analyzed with bioinformatics tools. Results. The study generated envelope gene sequences of DENV-1 and DENV-2 serotypes. Our study revealed a rapid dispersal and wide distribution of the cosmopolitan DENV-2 genotype in several regions of Peru in 2022, as well as the spread of DENV-1 genotype V to new Peruvian regions, along with the cosmopolitan DENV-2 genotype. Conclusions. Our findings suggest the urgent need to strengthen epidemiological and genomic surveillance systems to understand and control the spread of circulating DENV genotypes in Peru. This will allow a more rapid response, as well as the monitoring of its potential dissemination to other countries in the Americas.
- 4 December 2024
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 111 (6) , 1290-1294
Serologic Evidence for Early SARS–CoV-2 Circulation in Lima, Peru, 2020
: During early 2021, Peru had the highest COVID-19–associated per-capita mortality rate. Socioeconomic inequality, insufficiently prepared healthcare, and surveillance systems are factors explaining the mortality rate, which can be severely worsened by early undetected SARS–CoV-2 circulation. We tested 1,441 individuals with fever sampled during August 2019–May 2021, several months before the first SARS–CoV-2 seroprevalence study available so far in Lima, Peru, for SARS–CoV-2–specific antibodies. The testing algorithm included a chemiluminescence immunoassay and surrogate virus neutralization test. Early positive samples (N = 24) from January–March 2020 were further tested using a plaque-reduction neutralization test (PRNT) and avidity test against the SARS–CoV-2 spike and nucleoprotein. None of the early samples were PRNT-confirmed, in contrast to 81.8% (18/22) of a subsample from April 2020 onward (Fisher exact test; P 1 during February–March 2020. Early introduction of SARS-CoV-2 thus contributed to the high COVID-19 mortality rate in Peru. Emphasizing the role of diagnostic confirmation in understanding the pandemic’s trajectory, this study highlights the importance of early detection and accurate testing in managing infectious disease outbreaks.
- 4 December 2024
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 111 (6) , 1290-1294
Serologic Evidence for Early SARS–CoV-2 Circulation in Lima, Peru, 2020
: During early 2021, Peru had the highest COVID-19–associated per-capita mortality rate. Socioeconomic inequality, insufficiently prepared healthcare, and surveillance systems are factors explaining the mortality rate, which can be severely worsened by early undetected SARS–CoV-2 circulation. We tested 1,441 individuals with fever sampled during August 2019–May 2021, several months before the first SARS–CoV-2 seroprevalence study available so far in Lima, Peru, for SARS–CoV-2–specific antibodies. The testing algorithm included a chemiluminescence immunoassay and surrogate virus neutralization test. Early positive samples (N = 24) from January–March 2020 were further tested using a plaque-reduction neutralization test (PRNT) and avidity test against the SARS–CoV-2 spike and nucleoprotein. None of the early samples were PRNT-confirmed, in contrast to 81.8% (18/22) of a subsample from April 2020 onward (Fisher exact test; P 1 during February–March 2020. Early introduction of SARS-CoV-2 thus contributed to the high COVID-19 mortality rate in Peru. Emphasizing the role of diagnostic confirmation in understanding the pandemic’s trajectory, this study highlights the importance of early detection and accurate testing in managing infectious disease outbreaks.